The contract developer and manufacturer has significant experience in the analysis of both small and large molecules, and a range of product types including peptides and biologics
Almac Group, the global contract development and manufacturing organisation, has expanded its global analytical service capabilities to span the UK, Europe and North America.
Following the successful acquisition of BioClin Research Laboratories in 2017, Almac’s Sciences Business Unit has united its world-class capabilities to form an analytical group to meet the varying demands required within its clients’ development programmes.
From 1 October, BioClin will rename under the Almac Sciences brand, further strengthening its offering and presenting a unified platform within the pharmaceutical industry.
Employing 150 analysts working in GMP/GLP environments from its 3 locations in Craigavon, UK; Athlone, Ireland; and Souderton, Pennsylvania, North America, Almac has significant experience in the analysis of both small and large molecules, and a range of product types including peptides, biologics, conjugates, potents and controlled substances.
To satisfy client demand, resource at Almac’s PA based facility has also increased by 30%. The 2500 ft2 laboratory provides GMP analytical support to the pharmaceutical industry including analytical method development and validation, GMP stability studies and clinical and commercial product release.
Dr Stephen Barr, President and Managing Director of Almac Sciences, commented: “We are excited to present to the industry a unified analytical offering to our clients under the Almac name. The investments we continue to make highlights the commitment we have to our global client base to meet their growing clinical and commercial requirements.”
Almac will be exhibiting at CPhI, stand 3A31.